NI201900039A - Derivados de 6, 7, 8, 9-tetrahidro-3h-pirazolo[4, 3-f] isoquinolina útiles en el tratamiento del cáncer - Google Patents
Derivados de 6, 7, 8, 9-tetrahidro-3h-pirazolo[4, 3-f] isoquinolina útiles en el tratamiento del cáncerInfo
- Publication number
- NI201900039A NI201900039A NI201900039A NI201900039A NI201900039A NI 201900039 A NI201900039 A NI 201900039A NI 201900039 A NI201900039 A NI 201900039A NI 201900039 A NI201900039 A NI 201900039A NI 201900039 A NI201900039 A NI 201900039A
- Authority
- NI
- Nicaragua
- Prior art keywords
- treatment
- tetrahidro
- pirazolo
- isoquinoline
- cancer
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662411799P | 2016-10-24 | 2016-10-24 | |
| US201662435159P | 2016-12-16 | 2016-12-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NI201900039A true NI201900039A (es) | 2020-05-15 |
Family
ID=60083331
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NI201900039A NI201900039A (es) | 2016-10-24 | 2019-04-24 | Derivados de 6, 7, 8, 9-tetrahidro-3h-pirazolo[4, 3-f] isoquinolina útiles en el tratamiento del cáncer |
Country Status (37)
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3355884T3 (da) | 2015-10-01 | 2021-08-02 | Olema Pharmaceuticals Inc | Tetrahydro-1h-pyrido[3,4-b]indol-antiøstrogenlægemidler |
| WO2017174757A1 (en) * | 2016-04-08 | 2017-10-12 | F. Hoffmann-La Roche Ag | Tetrahydroisoquinoline estrogen receptor modulators and uses thereof |
| TW201803870A (zh) | 2016-04-20 | 2018-02-01 | 阿斯特捷利康公司 | 化學化合物 |
| TW201815789A (zh) | 2016-07-25 | 2018-05-01 | 瑞典商阿斯特捷利康公司 | 化合物 |
| TWI735681B (zh) | 2016-10-24 | 2021-08-11 | 瑞典商阿斯特捷利康公司 | 化合物 |
| SI3555097T1 (sl) | 2016-12-16 | 2022-09-30 | Janssen Pharmaceutica Nv | Imidazo(4,5-d)pirolo(2,3-b)piridinske spojine kot zaviralci janus kinaz |
| JOP20190144A1 (ar) | 2016-12-16 | 2019-06-16 | Janssen Pharmaceutica Nv | إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز |
| TWI831738B (zh) | 2016-12-16 | 2024-02-11 | 美商瑞塔醫藥有限責任公司 | 用於抑制ＲＯＲγ及其他用途的嘧啶三環烯酮衍生物 |
| PL3494116T3 (pl) | 2017-01-30 | 2020-04-30 | Astrazeneca Ab | Modulatory receptora estrogenowego |
| WO2019002441A1 (en) * | 2017-06-29 | 2019-01-03 | Astrazeneca Ab | CHEMICAL COMPOUNDS |
| WO2019002442A1 (en) * | 2017-06-29 | 2019-01-03 | Astrazeneca Ab | CHEMICAL COMPOUNDS |
| CA3082276C (en) * | 2017-11-14 | 2022-08-16 | Anlin Pharmaceuticals, Llc | Heterocyclic compounds and their application in medicine |
| JP7498122B2 (ja) | 2018-06-15 | 2024-06-11 | リアタ ファーマシューティカルズ インコーポレイテッド | ＩＬ－１７およびＲＯＲγの阻害用のピラゾール化合物およびイミダゾール化合物 |
| TW202016110A (zh) | 2018-06-15 | 2020-05-01 | 比利時商健生藥品公司 | Ｊａｋ激酶家族之小分子抑制劑 |
| EP3810141A1 (en) | 2018-06-20 | 2021-04-28 | Reata Pharmaceuticals, Inc. | Cysteine-dependent inverse agonists of nuclear receptors ror-gamma/ror-gamma-t and methods of treating diseases or disorders therewith |
| CA3109090A1 (en) | 2018-08-17 | 2020-02-20 | F. Hoffmann-La Roche Ag | Diagnostic and therapeutic methods for the treatment of breast cancer |
| CN109053524A (zh) * | 2018-09-11 | 2018-12-21 | 山东谛爱生物技术有限公司 | 一种N-Boc-3-羟基氮杂环丁烷的制备方法 |
| KR20220034129A (ko) | 2019-07-07 | 2022-03-17 | 올레마 파마슈티컬스 인코포레이티드 | 에스트로겐 수용체 길항제 요법 |
| NZ790033A (en) * | 2019-12-20 | 2025-09-26 | Recurium Ip Holdings Llc | Combinations |
| KR20220125272A (ko) | 2020-01-10 | 2022-09-14 | 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 | 트리사이클릭 테트라하이드로이소퀴놀린 유도체, 이를 제조하기 위한 방법 및 의료분야에서 이의 용도 |
| MX2022013391A (es) * | 2020-04-24 | 2022-11-30 | Astrazeneca Ab | Pauta posologica para el tratamiento del cancer. |
| PH12022552755A1 (en) * | 2020-04-24 | 2024-03-25 | Astrazeneca Ab | Pharmaceutical formulations |
| CA3178707A1 (en) | 2020-05-15 | 2021-11-18 | Peng GU | Pyrrolidine compound and use thereof |
| WO2021249533A1 (zh) * | 2020-06-12 | 2021-12-16 | 江苏先声药业有限公司 | 雌激素受体调节剂化合物及其用途 |
| US12415799B2 (en) | 2020-06-28 | 2025-09-16 | Zhejiang Yangli Pharmaceutical Technology Co., Ltd. | Indazole-fused cyclic compound |
| CN114105977B (zh) * | 2020-08-28 | 2023-09-01 | 先声再明医药有限公司 | 雌激素受体调节剂化合物及其用途 |
| KR20220107752A (ko) | 2021-01-26 | 2022-08-02 | 충북대학교 산학협력단 | 피라졸로퀴놀린 유도체 및 이의 항암제로서의 용도 |
| CN116669729A (zh) * | 2021-02-08 | 2023-08-29 | 贝达药业股份有限公司 | 杂芳基并哌啶类衍生物及其药物组合物和应用 |
| MX2023010642A (es) | 2021-03-11 | 2023-11-28 | Janssen Pharmaceutica Nv | Lorpucitinib para uso en el tratamiento de trastornos mediados por jak. |
| JP2024546191A (ja) * | 2021-12-28 | 2024-12-17 | 深▲セン▼揚歴医薬技術有限公司 | テトラヒドロシクロヘプタインダゾール化合物の塩形、結晶 |
| KR20250089532A (ko) | 2022-10-17 | 2025-06-18 | 아스트라제네카 아베 | 암 치료를 위한 serd의 조합 |
| WO2024100236A1 (en) | 2022-11-11 | 2024-05-16 | Astrazeneca Ab | Combination therapies for the treatment of cancer |
| US20240180893A1 (en) | 2022-11-17 | 2024-06-06 | Astrazeneca Ab | Methods of treatment of breast cancer |
| CN121079090A (zh) | 2023-05-11 | 2025-12-05 | 阿斯利康(瑞典)有限公司 | 用于治疗癌症的parp1抑制剂和选择性雌激素降解剂的组合 |
| WO2025175249A1 (en) * | 2024-02-14 | 2025-08-21 | Olema Pharmaceuticals, Inc. | Estrogen receptor modulators and uses thereof |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| MXPA03001169A (es) | 2000-08-10 | 2003-06-30 | Pharmacia Italia Spa | Biciclo-pirazoles activos como inhibidores de quinasa, proceso para su preparacion y composiciones farmaceuticas que comprenden los mismos. |
| WO2006101434A1 (en) | 2005-03-22 | 2006-09-28 | Astrazeneca Ab | NOVEL TETRAHYDRO-1H-PYRIDO [4,3-b] INDOLE DERIVATIVES AS CB1’ RECEPTOR LIGANDS |
| FR2884252B1 (fr) | 2005-04-08 | 2007-05-18 | Aventis Pharma Sa | Nouveaux derives d'isoindoles, compositions les contenant, leur preparation et leurs utilisations pharmaceutiques notamment en tant qu'inhibiteurs d'activites de la proteine chaperone hsp90 |
| AR058223A1 (es) | 2005-11-25 | 2008-01-23 | Palau Pharma Sa | Un comuesto de derivados de pirazoloisoquinolina, un procedimiento para l a preparacion de dicho compuesto y una composicion farmaceutica que comprende dicho compuesto |
| EP2223925A1 (en) | 2006-10-09 | 2010-09-01 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| US20120157401A1 (en) | 2009-05-27 | 2012-06-21 | Ptc Therapeutics, Inc. | Methods for treating neurofibromatosis |
| WO2010138659A1 (en) | 2009-05-27 | 2010-12-02 | Ptc Therapeutics, Inc. | Methods for treating brain tumors |
| CN102480957A (zh) | 2009-05-27 | 2012-05-30 | Ptc医疗公司 | 治疗癌症及非肿瘤病症的方法 |
| JP2013528223A (ja) | 2010-06-10 | 2013-07-08 | アラゴン ファーマシューティカルズ，インク． | エストロゲン受容体モジュレーターおよびその用途 |
| US8853423B2 (en) | 2010-06-17 | 2014-10-07 | Seragon Pharmaceuticals, Inc. | Indane estrogen receptor modulators and uses thereof |
| EP2655367B1 (en) * | 2010-12-24 | 2016-07-06 | Merck Sharp & Dohme B.V. | N-substituted azetidine derivatives |
| US9193714B2 (en) | 2011-12-14 | 2015-11-24 | Seragon Pharmaceuticals, Inc. | Fluorinated estrogen receptor modulators and uses thereof |
| LT3004090T (lt) | 2013-05-28 | 2018-01-10 | Astrazeneca Ab | Cheminiai junginiai |
| CN105451735B (zh) | 2013-06-19 | 2019-01-11 | 西拉根制药公司 | 氮杂环丁烷雌激素受体调节剂和其用途 |
| JP6576916B2 (ja) | 2013-06-19 | 2019-09-18 | セラゴン ファーマシューティカルズ， インク． | エストロゲン受容体モジュレーター及びその使用 |
| WO2015092634A1 (en) | 2013-12-16 | 2015-06-25 | Novartis Ag | 1,2,3,4-tetrahydroisoquinoline compounds and compositions as selective estrogen receptor antagonists and degraders |
| WO2016097073A1 (en) | 2014-12-18 | 2016-06-23 | F. Hoffmann-La Roche Ag | Derivatives of 2,3-diphenylchromene useful for the treatment of cancer |
| CN107108611B (zh) | 2014-12-18 | 2020-09-25 | 豪夫迈·罗氏有限公司 | 四氢-吡啶并[3,4-b]吲哚雌激素受体调节剂及其用途 |
| US9845291B2 (en) | 2014-12-18 | 2017-12-19 | Genentech, Inc. | Estrogen receptor modulators and uses thereof |
| WO2016174551A1 (en) | 2015-04-27 | 2016-11-03 | Pfizer Inc. | Anti-estrogenic compounds |
| EP3303326B1 (en) | 2015-05-26 | 2020-12-16 | H. Hoffnabb-La Roche Ag | Heterocyclic estrogen receptor modulators and uses thereof |
| RU2730508C2 (ru) * | 2015-06-16 | 2020-08-24 | Цзянсу Хэнжуй Медицин Ко., Лтд. | Производное пиперидина, способ его получения и его фармацевтическое применение |
| CN106518768B (zh) | 2015-09-15 | 2021-07-02 | 江苏恒瑞医药股份有限公司 | 丙烯酸类衍生物、其制备方法及其在医药上的应用 |
| DK3355884T3 (da) | 2015-10-01 | 2021-08-02 | Olema Pharmaceuticals Inc | Tetrahydro-1h-pyrido[3,4-b]indol-antiøstrogenlægemidler |
| HK1258851A1 (zh) | 2015-11-09 | 2019-11-22 | 豪夫迈‧罗氏有限公司 | 四氢萘雌激素受体调节剂及其用途 |
| JP6592197B2 (ja) | 2015-11-12 | 2019-10-16 | 浙江海正薬業股▲ふん▼有限公司Ｚｈｅｊｉａｎｇ Ｈｉｓｕｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌ ＣＯ．，ＬＴＤ． | アクリル酸誘導体、製造方法、および医薬としてのその使用 |
| CN107428721B (zh) | 2015-12-22 | 2020-07-28 | 江苏恒瑞医药股份有限公司 | 苯并哌啶类衍生物、其制备方法及其在医药上的应用 |
| WO2017174757A1 (en) * | 2016-04-08 | 2017-10-12 | F. Hoffmann-La Roche Ag | Tetrahydroisoquinoline estrogen receptor modulators and uses thereof |
| TW201803870A (zh) | 2016-04-20 | 2018-02-01 | 阿斯特捷利康公司 | 化學化合物 |
| WO2017182495A1 (en) * | 2016-04-20 | 2017-10-26 | Astrazeneca Ab | Indazole derivatives that down-regulate the estrogen receptor and possess anti-cancer activity |
| WO2017192991A1 (en) | 2016-05-06 | 2017-11-09 | Xavier University Of Louisiana | Selective estrogen receptor down-regulators (serds) |
| WO2018001232A1 (zh) | 2016-06-29 | 2018-01-04 | 浙江海正药业股份有限公司 | 丙烯酸类衍生物及其制备方法和其在医药上的用途 |
| TW201815789A (zh) | 2016-07-25 | 2018-05-01 | 瑞典商阿斯特捷利康公司 | 化合物 |
| CN107814798B (zh) | 2016-09-14 | 2020-11-03 | 四川科伦博泰生物医药股份有限公司 | 3-取代丙烯酸类化合物及其制备方法和用途 |
| US20180072711A1 (en) | 2016-09-15 | 2018-03-15 | Arvinas, Inc. | Indole derivatives as estrogen receptor degraders |
| BR102016024814A2 (pt) | 2016-10-24 | 2018-05-08 | Aché Laboratórios Farmacêuticos S.A. | composto, processo de obtenção do composto, composição farmacêutica, uso do composto e método de tratamento de desordens psiquiátricas e/ou distúrbios do sono |
| TWI735681B (zh) * | 2016-10-24 | 2021-08-11 | 瑞典商阿斯特捷利康公司 | 化合物 |
| SI3555097T1 (sl) | 2016-12-16 | 2022-09-30 | Janssen Pharmaceutica Nv | Imidazo(4,5-d)pirolo(2,3-b)piridinske spojine kot zaviralci janus kinaz |
| TWI831738B (zh) | 2016-12-16 | 2024-02-11 | 美商瑞塔醫藥有限責任公司 | 用於抑制ＲＯＲγ及其他用途的嘧啶三環烯酮衍生物 |
| JOP20190144A1 (ar) | 2016-12-16 | 2019-06-16 | Janssen Pharmaceutica Nv | إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز |
| EA036112B1 (ru) | 2016-12-16 | 2020-09-29 | Эли Лилли Энд Компани | 7-фенилэтиламино-4h-пиримидо[4,5-d][1,3]оксазин-2-оновые соединения в качестве ингибиторов мутантных idh1 и idh2 |
| AU2017374992A1 (en) | 2016-12-16 | 2019-06-20 | Basf Se | Pesticidal compounds |
| CN110325530B (zh) | 2016-12-16 | 2022-01-11 | 辉瑞大药厂 | Glp-1受体激动剂及其用途 |
| MX393050B (es) | 2017-01-30 | 2025-03-24 | Chiesi Farm Spa | Derivados de amida de tirosina como inhibidores de rho-cinasa. |
-
2017
- 2017-10-13 TW TW106135012A patent/TWI735681B/zh active
- 2017-10-13 CN CN201780064567.7A patent/CN109843888B/zh active Active
- 2017-10-13 SM SM20190602T patent/SMT201900602T1/it unknown
- 2017-10-13 DK DK17783857T patent/DK3433256T3/da active
- 2017-10-13 HR HRP20220255TT patent/HRP20220255T1/hr unknown
- 2017-10-13 CA CA3040040A patent/CA3040040A1/en active Pending
- 2017-10-13 SI SI201731087T patent/SI3640251T1/sl unknown
- 2017-10-13 WO PCT/EP2017/076191 patent/WO2018077630A1/en not_active Ceased
- 2017-10-13 CN CN202210381693.8A patent/CN114656464B/zh active Active
- 2017-10-13 MY MYPI2019002161A patent/MY205300A/en unknown
- 2017-10-13 NZ NZ753459A patent/NZ753459A/en unknown
- 2017-10-13 PT PT177838570T patent/PT3433256T/pt unknown
- 2017-10-13 UA UAA201905126A patent/UA125824C2/uk unknown
- 2017-10-13 SM SM20220098T patent/SMT202200098T1/it unknown
- 2017-10-13 DK DK19189010.2T patent/DK3640251T3/da active
- 2017-10-13 EP EP17783857.0A patent/EP3433256B1/en active Active
- 2017-10-13 PE PE2019000845A patent/PE20191078A1/es unknown
- 2017-10-13 RS RSP20191371 patent/RS59445B1/sr unknown
- 2017-10-13 PL PL17783857T patent/PL3433256T3/pl unknown
- 2017-10-13 AU AU2017349797A patent/AU2017349797B2/en active Active
- 2017-10-13 JO JOP/2019/0090A patent/JOP20190090B1/ar active
- 2017-10-13 KR KR1020197014062A patent/KR102178692B1/ko active Active
- 2017-10-13 CR CR20190204A patent/CR20190204A/es unknown
- 2017-10-13 PL PL19189010T patent/PL3640251T3/pl unknown
- 2017-10-13 HU HUE19189010A patent/HUE057524T2/hu unknown
- 2017-10-13 ES ES19189010T patent/ES2907759T3/es active Active
- 2017-10-13 LT LTEP19189010.2T patent/LT3640251T/lt unknown
- 2017-10-13 JP JP2019520525A patent/JP6744489B2/ja active Active
- 2017-10-13 PT PT191890102T patent/PT3640251T/pt unknown
- 2017-10-13 ME MEP-2019-306A patent/ME03547B/me unknown
- 2017-10-13 MX MX2019004685A patent/MX382331B/es unknown
- 2017-10-13 LT LT17783857T patent/LT3433256T/lt unknown
- 2017-10-13 SG SG11201903182XA patent/SG11201903182XA/en unknown
- 2017-10-13 SI SI201730111T patent/SI3433256T1/sl unknown
- 2017-10-13 HU HUE17783857A patent/HUE045714T2/hu unknown
- 2017-10-13 ES ES17783857T patent/ES2751902T3/es active Active
- 2017-10-13 EP EP19189010.2A patent/EP3640251B1/en active Active
- 2017-10-13 US US15/782,904 patent/US10131663B2/en active Active
-
2018
- 2018-10-09 US US16/155,041 patent/US10590130B2/en active Active
-
2019
- 2019-02-01 ZA ZA2019/00694A patent/ZA201900694B/en unknown
- 2019-04-16 PH PH12019500830A patent/PH12019500830A1/en unknown
- 2019-04-18 CL CL2019001077A patent/CL2019001077A1/es unknown
- 2019-04-18 CO CONC2019/0003950A patent/CO2019003950A2/es unknown
- 2019-04-22 IL IL266245A patent/IL266245B/en active IP Right Grant
- 2019-04-23 DO DO2019000104A patent/DOP2019000104A/es unknown
- 2019-04-23 EC ECSENADI201928657A patent/ECSP19028657A/es unknown
- 2019-04-24 NI NI201900039A patent/NI201900039A/es unknown
- 2019-10-24 CY CY20191101110T patent/CY1122566T1/el unknown
-
2020
- 2020-01-28 US US16/774,268 patent/US10961241B2/en active Active
- 2020-07-30 JP JP2020129457A patent/JP6993477B2/ja active Active
-
2021
- 2021-02-17 US US17/177,617 patent/US12077530B2/en active Active
-
2022
- 2022-02-23 CY CY20221100160T patent/CY1125292T1/el unknown
-
2024
- 2024-07-17 US US18/775,391 patent/US20240383895A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NI201900039A (es) | Derivados de 6, 7, 8, 9-tetrahidro-3h-pirazolo[4, 3-f] isoquinolina útiles en el tratamiento del cáncer | |
| ECSP20070854A (es) | Compuestos heteroaril tetracíclicos | |
| DOP2021000183A (es) | Compuestos tricíclicos condensados útiles como agentes anticancerígenos | |
| UY38001A (es) | Compuestos que inhiben las proteínas ras mutantes g12c | |
| CO2018004857A2 (es) | Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer | |
| UY35590A (es) | Nuevos compuestos para el tratamiento del cáncer | |
| CR20150628A (es) | Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades | |
| ECSP24028270A (es) | Compuestos espirocíclicos | |
| UY35275A (es) | Derivados de aminopirazina | |
| CO2019008941A2 (es) | Moduladores del receptor de estrógeno | |
| CR20160527A (es) | Derivados de carboxamida | |
| ECSP18056196A (es) | Derivados de indano | |
| EA201990943A1 (ru) | 6,7,8,9-ТЕТРАГИДРО-3H-ПИРАЗОЛО[4,3-f]ИЗОХИНОЛИНОВЫЕ ПРОИЗВОДНЫЕ, ПРИМЕНИМЫЕ В ЛЕЧЕНИИ РАКА |